Delivery Order SPE2DB22D3401-SPE2DB25FT2VS

Award Date 3/24/25
Potential Completion Date 3/25/25
Potential Value $21K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg Ondansetron orally disintegrating tablets. The contract has a ceiling value of $3,222.53 and an ultimate completion date of August 23, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999, which AmerisourceBergen holds with the DLA Troop Support Medical to provide a wide range...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg ondansetron orally disintegrating tablets. The contract has a ceiling value of $3,482.29 and a performance period that runs through January 22, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. The IDC serves as a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,565,481,629 units of the 8 mg Ondansetron orally disintegrating tablet in 30-count packages. The firm-fixed-price contract, valued at $3,182.49, has an ultimate completion date of August 19, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply 4 mg Ondansetron Orally Disintegrating Tablets in 30-count packages. The contract, valued at $2,801.40, is a firm fixed-price Delivery Order with a performance period through August 15, 2024. It is not set-aside for any socioeconomic program. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of 4,566,374 units of 8 mg Ondansetron Orally Disintegrating Tablets (NDC 4566374201). The firm-fixed-price contract, valued at $28,591.30, has a period of performance through November 8, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a comprehensive...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of 4 milligram Ondansetron orally disintegrating tablets in 30-count packages. The $2,715.52 firm-fixed-price contract has an ultimate completion date of August 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,147.40 firm fixed-price contract is for the supply of 4 mg Ondansetron Orally Disintegrating Tablets in 30-count packages. The ultimate completion date is February 7, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg Ondansetron Orally Disintegrating Tablets in 30-count packages. The contract has a firm fixed price of $1,539.86 and a completion date of February 20, 2025. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 4mg Ondansetron orally disintegrating tablets. The $14,775.36 firm-fixed price contract does not have a set-aside designation and has an ultimate completion date of August 5, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999, to provide a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of 4 mg Ondansetron orally disintegrating tablets in 30-count packages, with a ceiling value of $10,433.62 and a period of performance through June 4, 2024. The contract is a firm-fixed-price arrangement with no set-aside designation, indicating open competition. AmerisourceBergen holds a...
  • SPE2DB22D3401
    Indefinite Delivery Contract
  • SPE2DB22D3401-SPE2DB25FT2VS
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg Ondansetron Orally Disintegrating Tablets in quantities of 30 per package. The award has a ceiling value of $20,590.05 and runs from March 2025 to March 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/29/25, 1:15 AM